We are pleased to invite investors and analysts to participate in our virtual event on Thursday, 31 October 2024, to highlight Phase II trontinemab data presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting, from 29 October - 1 November 2024.   16:00 - 17:00 CET / 15:00 - 16:00 GMT 11:00 - 12:00 am EDT / 8:00 - 9:00 am PDT   The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CET on the day of the event. > click here     Agenda Introduction Bruno Eschli, Head of Investor Relations   Roche in Alzheimer’s Disease Azad Bonni, SVP and Global Head of Neuroscience & Rare Diseases at pRED   Trontinemab data at CTAD 2024 Luka Kulic, Therapeutic Area Leader Dementias and Expert Medical Director in Neuroscience & Rare Diseases, at pRED   Elecsys Biomarker data at CTAD 2024 Margherita Carboni, Indication Lead, Neurology and Clinical Development Lead in Neurology, Endocrinology and OBGYN at Roche Diagnostics   Q&A   Access to virtual event (pre-registration required) Please pre-register for our webinar here*.   Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.   A replay of the webcast will be available via > ir.roche.com   *privacy notice   Best regards,

Bruno Eschli Head of Investor Relations	Rishard Salie Investor Relations Officer
Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

get the latest news and updates to your inbox.